The function of AarF domain-containing kinase 1 (ADCK1) has not been thoroughly revealed. Here we identified that ADCK1 utilizes YME1-like 1 ATPase (YME1L1) to control optic atrophy 1 (OPA1) and inner membrane mitochondrial protein (IMMT) in regulating mitochondrial dynamics and cristae structure. We firstly observed that a serious developmental impairment occurred in
Drosophila ADCK1
(
dADCK1
) deletion mutant, resulting in premature death before adulthood. By using temperature sensitive ubiquitously expression driver
tub-Gal80
ts
/tub-Gal4
or muscle-specific expression driver
mhc-Gal4
, we observed severely defective locomotive activities and structural abnormality in the muscle along with increased mitochondrial fusion in the
dADCK1
knockdown flies. Moreover, decreased mitochondrial membrane potential, ATP production and survival rate along with increased ROS and apoptosis in the flies further demonstrated that the structural abnormalities of mitochondria induced by
dADCK1
knockdown led to their functional abnormalities. Consistent with the ADCK1 loss-of-function data in
Drosophila
, ADCK1 over-expression induced mitochondrial fission and clustering in addition to destruction of the cristae structure in
Drosophila
and mammalian cells. Interestingly, knockdown of
YME1L1
rescued the phenotypes of ADCK1 over-expression. Furthermore, genetic epistasis from fly genetics and mammalian cell biology experiments led us to discover the interactions among IMMT, OPA1 and ADCK1. Collectively, these results established a mitochondrial signaling pathway composed of ADCK1, YME1L1, OPA1 and IMMT, which has essential roles in maintaining mitochondrial morphologies and functions in the muscle.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.